The company is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer. With this deal, Brooklyn extends its option exercise period for entering into a license agreement with Factor Bioscience and Novellus through May 21.

The license would allow Brooklyn to utilize a patented process to seek to develop gene edited compounds using mRNA, which preclinical data suggest to be more efficient, nonimmunogenic, and nonmutagenic, for treatment of several solid tumor and liquid indications such as sickle cell anemia, as well as a number of additional inherited disorders.

The licensed platform would include mRNA cell reprogramming, mRNA-based gene editing, a proprietary gene editing protein, and the proprietary ToRNAdo lipid delivery system that provides delivery of mRNA ex vivo and in vivo to skin, brain, eye, and lung tissue.

Gene Schaefer joins NIIMBL as senior fellow
Gene Schaefer, ScD, has joined the U.S. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) as senior fellow, effective April...

ImmunoScape raises $14M for its deep immunomics platform
ImmunoScape has completed a financing round that raised $14 million to enlarge its Singapore-based team, further its expansion into the U.S., and...

Waters, Genovis team up on automated CQA characterization
Waters and Genovis are working together to develop and market routine biopharmaceutical characterization workflows of critical quality attributes (CQAs)...

Avantor to acquire liquid handling manufacturer Ritter for $1B
Avantor has entered into an agreement to acquire liquid handling consumables firm Ritter and its affiliates for approximately $1.05 billion in an...

Chime secures $190M to expand biopharma manufacturing
China-based contract development and manufacturing organization Chime Biologics has secured $190 million to finance the second phase of its biomanufacturing...